Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study

Background Insights into the burden, needs and treatment of migraine from internet-based surveys in diverse real-world migraine populations are needed, especially at a time when novel preventive migraine medications are becoming part of the therapeutic armamentarium. The objectives of this analysis...

ver descrição completa

Detalhes bibliográficos
Autores: Pascual Gómez, Julio, Panni, Tommaso, Dell'Agnello, Grazia, Gonderten, Saygin, Novick, Diego, Evers, Stefan
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/30212
Acesso em linha:https://hdl.handle.net/10902/30212
Access Level:acceso abierto
Palavra-chave:OVERCOME (EU)
Migraine
Severe headache
Preventive medication
Treatment patterns
Treatment satisfaction
id ES_759c0ee51153ea03d14a2c02fe9c8472
oai_identifier_str oai:repositorio.unican.es:10902/30212
network_acronym_str ES
network_name_str España
repository_id_str
spelling Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) studyPascual Gómez, JulioPanni, TommasoDell'Agnello, GraziaGonderten, SayginNovick, DiegoEvers, StefanOVERCOME (EU)MigraineSevere headachePreventive medicationTreatment patternsTreatment satisfactionBackground Insights into the burden, needs and treatment of migraine from internet-based surveys in diverse real-world migraine populations are needed, especially at a time when novel preventive migraine medications are becoming part of the therapeutic armamentarium. The objectives of this analysis are to describe traditional preventive (orals and onabotulinum toxin A) treatment patterns in the OVERCOME (EU) study migraine cohort, as well as treatment patterns and patient satisfaction with current treatment in a subgroup of respondents eligible for migraine preventive medication. Methods The cross-sectional non-interventional OVERCOME (EU) study was conducted (October 2020-February 2021) via an online survey among adults (aged ≥18 years) resident in Germany or Spain. Participants, registered in existing online panels, who were willing to provide consent were considered. The migraine cohort included participants reporting headache/migraine in the past year, identified based on a validated migraine diagnostic questionnaire and/or self-reported physician diagnosis. A subgroup of survey respondents defined as eligible for migraine preventive medication at the point in time the cross-sectional survey was taken was also analysed. Variables assessed included sociodemographic and migraine-related clinical characteristics, preventive (traditional and calcitonin gene-related peptide monoclonal antibodies) treatment patterns and patient satisfaction with current treatment. Results are descriptive only. Results Of the 20,756 participants in the migraine cohort, 78.5% sought professional medical care, 50.8% received a migraine diagnosis and only 17.7% had ever used preventive medication. Half (53.3%) of participants currently using preventives took their most recent medication for six months or less. Most patients (73.9%) classified as eligible for preventive medication (based on headache frequency and/or at least moderate disability due to migraine) reported not using traditional preventives and many of those who did (66.8%) were not satisfied with their current standard of care. Conclusions Our findings highlight the low proportion of people diagnosed with migraine despite a higher rate of consultation and suggest the need for better access to treatment for people with migraine and new preventive therapies with improved efficacy and safety profiles to improve adherence and patient satisfaction.Funding: This work was supported by Eli Lilly and Company. Acknowledgements: We would like to thank Sue Williamson (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company.SpringerUniversidad de Cantabria20232023-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/30212Journal of Headache and Pain, 2023, 24, 88reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/302122026-06-02T12:39:31Z
dc.title.none.fl_str_mv Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
title Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
spellingShingle Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
Pascual Gómez, Julio
OVERCOME (EU)
Migraine
Severe headache
Preventive medication
Treatment patterns
Treatment satisfaction
title_short Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
title_full Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
title_fullStr Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
title_full_unstemmed Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
title_sort Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
dc.creator.none.fl_str_mv Pascual Gómez, Julio
Panni, Tommaso
Dell'Agnello, Grazia
Gonderten, Saygin
Novick, Diego
Evers, Stefan
author Pascual Gómez, Julio
author_facet Pascual Gómez, Julio
Panni, Tommaso
Dell'Agnello, Grazia
Gonderten, Saygin
Novick, Diego
Evers, Stefan
author_role author
author2 Panni, Tommaso
Dell'Agnello, Grazia
Gonderten, Saygin
Novick, Diego
Evers, Stefan
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv OVERCOME (EU)
Migraine
Severe headache
Preventive medication
Treatment patterns
Treatment satisfaction
topic OVERCOME (EU)
Migraine
Severe headache
Preventive medication
Treatment patterns
Treatment satisfaction
description Background Insights into the burden, needs and treatment of migraine from internet-based surveys in diverse real-world migraine populations are needed, especially at a time when novel preventive migraine medications are becoming part of the therapeutic armamentarium. The objectives of this analysis are to describe traditional preventive (orals and onabotulinum toxin A) treatment patterns in the OVERCOME (EU) study migraine cohort, as well as treatment patterns and patient satisfaction with current treatment in a subgroup of respondents eligible for migraine preventive medication. Methods The cross-sectional non-interventional OVERCOME (EU) study was conducted (October 2020-February 2021) via an online survey among adults (aged ≥18 years) resident in Germany or Spain. Participants, registered in existing online panels, who were willing to provide consent were considered. The migraine cohort included participants reporting headache/migraine in the past year, identified based on a validated migraine diagnostic questionnaire and/or self-reported physician diagnosis. A subgroup of survey respondents defined as eligible for migraine preventive medication at the point in time the cross-sectional survey was taken was also analysed. Variables assessed included sociodemographic and migraine-related clinical characteristics, preventive (traditional and calcitonin gene-related peptide monoclonal antibodies) treatment patterns and patient satisfaction with current treatment. Results are descriptive only. Results Of the 20,756 participants in the migraine cohort, 78.5% sought professional medical care, 50.8% received a migraine diagnosis and only 17.7% had ever used preventive medication. Half (53.3%) of participants currently using preventives took their most recent medication for six months or less. Most patients (73.9%) classified as eligible for preventive medication (based on headache frequency and/or at least moderate disability due to migraine) reported not using traditional preventives and many of those who did (66.8%) were not satisfied with their current standard of care. Conclusions Our findings highlight the low proportion of people diagnosed with migraine despite a higher rate of consultation and suggest the need for better access to treatment for people with migraine and new preventive therapies with improved efficacy and safety profiles to improve adherence and patient satisfaction.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/30212
url https://hdl.handle.net/10902/30212
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv Journal of Headache and Pain, 2023, 24, 88
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410992845225984
score 15.300719

Registos relacionados